Research programme: p53 function restorers - XenovaAlternative Names: p53 function restorers research programme - Xenova
Latest Information Update: 29 Jul 2004
At a glance
- Originator Xenova Group
- Class Small molecules
- Mechanism of Action Tumour suppressor protein p53 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jul 2004 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 03 Dec 1999 Preclinical development for Cancer in United Kingdom (Unknown route)